Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with an extremely variable course. Survival after diagnosis can range from months to decades and wide variability exists in the rate of disease progression and the incidence of disease-related complications among patients with CLL. Staging helps to define prognosis and to decide when to initiate therapy.
Objective: To asses response to oral alkylating therapy and to evaluate the adverse events that can complicate the disease itself or the treatment, including infections, autoimmune and other complications. The survival events are also been assessed.
Patients and methods: Forty nine Iraqi CLL patients, their age ranged between 40-90 years were followed with me

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence Philadelphia chromosome (Ph) which was created by a reciprocal translocation between chromosomes 9 and 22 (t [9;22] [q34;q11]. The approval of the 2nd generation TKI ( Nilotinib) takes the treatment of CML patients into new erea with more efficiency and mild to moderate adverse effects. This study was aimed at evaluation of molecular cytogenetic response by (FISH) for Nilotinib in Iraqi patients with assessment for electrolytes disturbances of Nilotinb by measuring a panel of electrolyte (Na+, K+, Ca++, PO4--- and Mg++) , where thirty Iraqi patients with CML who have resistance or no response to Imatinib treatment, attending to Baghdad Teaching Ho

Acute lymphoblastic leukemia which developed after first primary solid organ malignancy (1M) considered as secondary acute lymphoblastic leukemia (sALL) and it is rare. The observational study that researches for(sALL) in worldwide and even in Iraq is limited. This study investigated (sALL) among 50 (ALL) Iraqi patients (30 children; 20 adults). Five (4 female;1 male) out of  50 (ALL) patients (10%) were with(sALL) .They asked through questionnaire form about their age , 1M , latency period and immunophenotype .They were in 14-40 years age group and with previous malignancies breast , ovary, lung and thyroid cancers. The median latency period (from 1M to sALL) was 30 months. Four of (sALL) were with B cell immunophenotype , while on

Objective(s): To determine the impact of Chemotherapy upon the quality of life for patients with chronic myeloid
leukemia in Baghdad city.

Methodology: A descriptive study design was carried out The study was initiated from 30 January 2011 to October
2011.A purposive (non–probability) sample consisted of (130) patients with a chronic myeloid leukemia ,Who
attended to Baghdad Teaching Hospital and National Center for Research and Treatment of Hematology. The
sample criteria was the patients who were 18 years old and above, excluding the patients who suffered from
psychological problems and other chronic illnesses .A questionnaire was adopted and developed from European
Organization Research and treatment of Can

Chronic myeloid leukemia (CML) is a myeloproliferative disorders characterized by formation of Philadelphia chromosome. After disease development, several events may associate with the reduction of anti-tumor immunity. The present study was designed to investigate the immunological profile of innate and adaptive immune response in Iraqi patients with CML. Patients were grouped into untreated (UT), treated (T) with chemotherapy, while another apparently healthy individuals were recruited to represent the control (C) group. Methods: ELISA technique was used to estimate serum levels of GM-CSF, IL-1a, IL-8, IL2, INF-?, IL-4, and IL-10 while SRID was used to estimate serum levels of C4, IgM, IgA, and IgG. Results: Regarding to innate immune resp

Background:
Patients treated for pediatric malignancy are at high risk of parenterally transmitted viral hepatitis.
Objectives:
To detect the seroprevalence of hepatitis B and C viral infections in children with Acute Lymphoblastic Leukemia & identify some variables that could affect its
prevalence in these patients.
Patients and Methods:
One hundred fifty pediatric acute lymphoblastic leukemia patients, presented to Children Welfare Teaching Hospital, Baghdad, during the period from March 11th
2007 to July 31st 2007 were enrolled in this study; they were 103 males, 47 females, aged (2.25 months- 16 years). Sera of these patients were investigated for hepatitis
markers including HBsAg and A

Acute lymphoblastic leukemia (ALL) is one of the most common diseases , so in this study the serum level of malondialdehyde and its relationship with metanephrine was investigated in acute lymphoblastic leukemia patients over one month of treatment. Some biochemical parameters (serum glucose , total serum protein , malondialdehyde ,vitamin C, and metanephrine) changed as well as white blood cell count and blood hemoglobinlevelswere analyzed in sixty patients diagnosed with acute lymphoblastic leukemia over one month of treatment compared to healthy control group.Statistically significant increases (p<0.01) in white blood cell (WBC) count, mean concentrations of malondialdehyde (MDA) (p< 0.05) and metanephrine (p< 0.001) were observed in

Leukemia or cancer of the blood is the most common childhood cancer, Acute lymphoblastic leukemia (ALL), is the most common form of leukemia that occurs in children. It is characterized by the presence of too many immature white blood cells in the child’s blood and bone marrow, Acute lymphoblastic leukemia can occur in adults too, treatment is different for children. Children with ALL develop symptoms related to infiltration of blasts in the bone marrow, lymphoid system, and extramedullary sites, such as the central nervous system (CNS). Common constitutional indications consist of fatigue (50%), pallor (25%), fever (60%), and weight loss (26%). Infiltration of blast cells in the marrow cavity and periosteum often lead to bone

      The aim of the present study is to compare the biochemical action of the three vaccines taken in Iraq: Pfizer Biontech, AstraZeneca Oxford and Sinopharm based on biochemical parameters. Seventy COVID-19 Iraqi patients ( males and females ) were participated in the present study and classified into 7 groups : Gc :  COVID-19 patients ( without vaccine ) , Gp₁: COVID-19 patients took one dose of Pfizer Biontech, Gp₂ : COVID-19 patients took two doses of Pfizer Biontech, Ga₁ : patients took one dose of AstraZeneca Oxford vaccine , Ga₂: patients took two doses of AstraZeneca Oxford vaccine , Gs₁ : patients took one dose of Sinopharm vaccine and Gs₂: